Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|November 20, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
PD-1 and PD-L1 Antibodies in Lung Cancer
Author(s)Naiyer Rizvi, MD
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Advertisement
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Read about predictive biomarkers of
Articles in this issue
almost 13 years ago
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanomaalmost 13 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersalmost 13 years ago
Immunotherapy—An Increasingly Important Role in Oncologyalmost 13 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyalmost 13 years ago
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhDalmost 13 years ago
Checkpoint Inhibitors in Cancer Carealmost 13 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadealmost 13 years ago
Nivolumab Plus Ipilimumab in Advanced Melanomaalmost 13 years ago
The Outlook for ImmunotherapiesAdvertisement
Related to this article
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
4
Has CAR T Access Improved 1 Year After REMS Elimination?
5